Lower GI Bleeding (Non-acute)

📋 Key Information Summary

📋

Non-acute lower GI bleeding (LGIB) encompasses intermittent rectal bleeding not associated with haemodynamic instability and managed predominantly in primary care across Australia.
The most common causes of non-acute LGIB are haemorrhoids (internal and external), anal fissures, colonic diverticular disease, and inflammatory bowel disease (IBD).
Risk stratification begins with distinguishing the character of bleeding — bright red blood on wiping or streaked on stool (typically anorectal) versus dark red blood mixed within stool (suggests a more proximal colonic source).
Assess for haemodynamic stability (heart rate, blood pressure, postural symptoms) even in non-acute presentations to exclude covert significant haemorrhage.
Alarm features mandating urgent referral include: age ≥45 years with new-onset bleeding, change in bowel habit, unintentional weight loss, iron deficiency anaemia, or a palpable abdominal/rectal mass.
Initial primary care evaluation should include a thorough history (dietary and medication causes, personal and family history of colorectal neoplasia, IBD, diverticular disease), digital rectal examination (DRE), and consideration of in-office anoscopy.
Baseline investigations include full blood count (FBC/CBC), serum ferritin, and iron studies to assess for iron deficiency anaemia — a red flag for colorectal malignancy until proven otherwise.
Patients aged ≥45–50 years with rectal bleeding should be referred for colonoscopic evaluation in line with the Australian National Bowel Cancer Screening Program (NBCSP) age thresholds and RACGP recommendations.
Faecal immunochemical test (FIT) is useful in risk stratification for colorectal cancer but does not replace colonoscopy in symptomatic patients with rectal bleeding.
Iron deficiency anaemia in the context of LGIB requires both investigation of the GI tract (upper and lower endoscopy) and oral or intravenous iron replacement — PBS-listed ferrous sulfate 325 mg PO daily is first-line.
Aboriginal and Torres Strait Islander peoples have higher rates of colorectal cancer and lower screening participation; culturally safe assessment, proactive screening engagement, and accessible referral pathways are essential.
Patients with known haemorrhoids or fissures who develop new or changing bleeding patterns must be re-evaluated — never attribute rectal bleeding solely to known benign pathology without excluding malignancy, particularly in those aged ≥50 years.

Introduction & Australian Epidemiology

Lower gastrointestinal bleeding (LGIB) refers to any haemorrhage originating distal to the ligament of Treitz, encompassing sources in the colon, rectum, and anus. Non-acute LGIB — characterised by intermittent, self-limited episodes without haemodynamic compromise — is one of the most common presentations in Australian general practice. While the majority of cases are attributable to benign anorectal pathology, a clinically significant minority harbour serious underlying conditions including colorectal carcinoma, inflammatory bowel disease, and angiodysplasia.

In Australia, rectal bleeding is reported by approximately 10–15% of adults in community surveys, with haemorrhoidal disease affecting an estimated 30–40% of the adult population at some point in their lifetime. Diverticular disease is increasingly prevalent with age, found in over 40% of Australians aged >65 years on colonoscopic or imaging studies. Colorectal cancer remains the third most commonly diagnosed cancer in Australia (excluding non-melanoma skin cancer) and the second leading cause of cancer-related mortality, with approximately 15,500 new cases diagnosed annually according to the Australian Institute of Health and Welfare (AIHW, 2023).

The Australian National Bowel Cancer Screening Program (NBCSP), offering biennial faecal immunochemical testing (FIT) to eligible Australians aged 50–74 years, has improved early detection. However, symptomatic patients with rectal bleeding require clinical assessment beyond screening pathways. Prompt differentiation between benign and sinister causes in primary care is essential to ensure timely referral and reduce mortality from colorectal malignancy.

⚠️

Clinical pearl: In Australian practice, rectal bleeding in any patient aged ≥50 years should be considered colorectal cancer until proven otherwise. Age-appropriate colonoscopic evaluation is mandatory — do not attribute bleeding to haemorrhoids without investigation.

Risk Stratification

Risk stratification in non-acute LGIB serves two primary objectives: (1) to identify patients who can be safely managed in primary care with conservative measures, and (2) to detect features that warrant urgent or semi-urgent specialist referral. Even in the non-acute setting, systematic assessment is essential to avoid delayed diagnosis of serious pathology.

Character of Bleeding

The appearance and pattern of bleeding provide important localising information:

Feature	Likely Source	Typical Causes	Significance
Bright red blood on toilet paper only	Distal anal canal / perianal	External haemorrhoids, anal fissure, perianal dermatitis	Usually benign — manage in primary care if age <45 and no alarm features
Bright red blood on surface of formed stool	Anorectal / distal rectum	Internal haemorrhoids, rectal polyp, proctitis	Low–moderate concern; investigate if recurrent or age ≥45
Bright red blood mixed into stool or in toilet bowl	Left colon / sigmoid / rectum	Diverticular disease, colorectal neoplasia, IBD, ischaemic colitis	Moderate–high concern; colonoscopy recommended
Dark red / maroon blood mixed with stool	Right colon / proximal colon	Angiodysplasia, right-sided diverticula, caecal carcinoma	High concern — colonoscopy indicated
Occult blood only (FIT positive, no visible bleeding)	Any colonic site	Polyps, colorectal cancer, angiodysplasia, NSAID-related mucosal injury	Significant — requires colonoscopic evaluation per NBCSP pathway

Haemodynamic Assessment

Even in non-acute presentations, a focused haemodynamic assessment should be performed:

Heart rate: Resting tachycardia (>100 bpm) may indicate occult blood loss or anxiety; compare with baseline if available.
Blood pressure: Hypotension (systolic <100 mmHg) or postural hypotension (systolic drop ≥20 mmHg on standing) suggests significant volume depletion — consider acute LGIB pathway.
Symptoms of anaemia: Fatigue, dyspnoea on exertion, dizziness, palpitations, or angina (in elderly patients) suggest chronic or subacute blood loss with resultant iron deficiency anaemia.
Transfusion history: Previous requirement for blood transfusion in the context of GI bleeding indicates a high-risk patient.

🚨

Acute escalation: If the patient is haemodynamically unstable (tachycardia, hypotension, postural symptoms), this is no longer a non-acute presentation — arrange emergency transfer to the nearest hospital with endoscopy and interventional radiology capabilities.

Anxiety Symptoms

Patients presenting with non-acute rectal bleeding frequently express significant anxiety about the possibility of cancer. Acknowledging and addressing these concerns while pursuing appropriate investigation is an important component of patient-centred care. Conversely, patients who minimise or have normalised their bleeding — particularly those with a long history of "haemorrhoids" — require careful re-evaluation to ensure no change in pattern has occurred.

Low Risk

Minor Anorectal Bleeding

Small amount of bright red blood on wiping or on stool surface only. No anaemia symptoms. Haemodynamically stable. Age <45, no family history of CRC, no change in bowel habit.

Setting: Primary care — manage conservatively; refer if persistent >4–6 weeks or if age ≥45

Moderate Risk

Recurrent or Mixed Bleeding

Blood mixed with stool (bright or dark red), recurrent episodes, mild anaemia symptoms (fatigue), or age ≥45 years. Haemodynamically stable.

Setting: Primary care + semi-urgent outpatient colonoscopy referral within 2–4 weeks

High Risk

Alarm Features Present

Iron deficiency anaemia, weight loss, change in bowel habit, family history of CRC in first-degree relative <60 years, palpable mass, or age ≥50 with new-onset bleeding.

Setting: Urgent specialist referral — colonoscopy within 2 weeks (fast-track cancer pathway)

Initial Evaluation in Primary Care

The primary care evaluation of non-acute LGIB aims to identify likely benign causes, detect alarm features, and determine the need for and urgency of further investigation. A structured approach ensures that serious pathology is not missed.

History

A comprehensive history should address the following domains:

Bleeding Characteristics

Duration and frequency of episodes (first episode vs. recurrent)
Volume of blood loss (drops on paper vs. streaks vs. splashing in toilet bowl vs. clots)
Colour: bright red (distal) vs. dark red/maroon (proximal)
Relationship to defaecation — blood on wiping only, on stool surface, or mixed through stool
Presence of mucus, pus, or faecal occult blood
Associated symptoms: pain with defaecation (fissure), prolapsing mass (haemorrhoids), tenesmus (rectal pathology)

Bowel Habit

Change in bowel habit — new constipation, diarrhoea, or alternating pattern (alarm feature for colorectal cancer)
Narrow or ribbon-like stools (may indicate left-sided colonic obstruction)
Straining at stool (associated with haemorrhoidal disease and fissures)
Nocturnal symptoms — nocturnal diarrhoea or bleeding suggests organic rather than functional disease

Risk Factors for Serious Pathology

Personal history: Colorectal polyps, colorectal cancer, IBD (Crohn's disease, ulcerative colitis), diverticular disease, previous colonoscopy findings
Family history: First-degree relative with colorectal cancer (especially if diagnosed <60 years) — increases risk 2–4 fold
Known haemorrhoids: Patients with a prior diagnosis of haemorrhoids who present with new or changed bleeding patterns require re-investigation
Medications: Anticoagulants (warfarin, DOACs), antiplatelet agents (aspirin, clopidogrel), NSAIDs — these may exacerbate bleeding from an existing lesion and do not explain the underlying cause
Systemic symptoms: Unintentional weight loss (>5% body weight in 6 months), fevers, night sweats, fatigue

Dietary and Benign Causes

Exclude dietary causes of red-coloured stool: beetroot, dragon fruit (pitaya), tomatoes, red food colouring, certain medications (iron tablets cause black stool, not red; rifampicin may cause red discolouration)
Constipation and straining — a very common precipitant of minor rectal bleeding from fissures and haemorrhoids
Recent antibiotic use (associated with Clostridioides difficile colitis, though usually presents acutely)

Physical Examination

A focused examination in primary care should include:

General assessment: Pallor (conjunctival, palmar), vital signs (HR, BP, postural measurements), signs of chronic disease
Abdominal examination: Palpation for masses, tenderness, organomegaly; auscultation for bruits (rare, but may suggest mesenteric vascular disease)
Digital rectal examination (DRE): Mandatory in all patients presenting with rectal bleeding. Assess for anal fissure, perianal skin tags, external haemorrhoids, rectal mass or polyp, and stool character (hard impacted stool, mucus, blood). Note: A normal DRE does not exclude significant proximal pathology.

💡

Anoscopy in primary care: Where available and within scope of practice, in-office anoscopy can visualise the distal anal canal and lower rectum, enabling direct identification of internal haemorrhoids, anal fissures, and distal rectal polyps. This can increase diagnostic confidence for benign anorectal causes but does not replace colonoscopy when indicated.

Investigations

The following baseline investigations should be requested in primary care for all patients presenting with non-acute rectal bleeding:

Essential Full Blood Count (FBC) MBS Item 65070. Assess haemoglobin (anaemia), mean cell volume (microcytic pattern suggests iron deficiency; normocytic may indicate chronic disease or acute loss), platelet count. Anaemia with Hb <120 g/L (males) or <110 g/L (females) warrants investigation.

Essential Serum Ferritin MBS Item 66800. Ferritin <30 µg/L is highly suggestive of iron deficiency (even within "normal" range). Ferritin <15 µg/L is diagnostic. Note: Ferritin is an acute-phase reactant — may be falsely elevated in inflammation; interpret with CRP.

Available Iron Studies (Serum Iron, Transferrin, Transferrin Saturation) MBS Item 66812. Transferrin saturation <20% confirms iron deficiency. Useful when ferritin is equivocal or in the setting of concurrent inflammation.

Available Faecal Immunochemical Test (FIT) Quantitative faecal haemoglobin testing. Available through NBCSP for ages 50–74. Can be requested privately (MBS Item 69487 via NBCSP pathway). FIT positivity in a symptomatic patient does NOT replace colonoscopy but supports urgency of referral. FIT is more sensitive and specific than older guaiac-based FOBT.

Available Inflammatory Markers (CRP, ESR) MBS Item 65085 (CRP). Useful to evaluate for IBD, infective colitis, or to interpret ferritin in the setting of inflammation. Elevated CRP with rectal bleeding warrants further investigation for IBD or malignancy.

Interpreting Iron Deficiency Anaemia in the Context of LGIB

Iron deficiency anaemia (IDA) in a patient with rectal bleeding is a significant finding that demands thorough investigation. In premenopausal women, menstrual blood loss is a common contributor and may coexist with GI pathology. In men and postmenopausal women, IDA in the setting of rectal bleeding is colorectal cancer until proven otherwise.

🚨

Red flag — Iron deficiency anaemia: Any adult with unexplained iron deficiency anaemia (ferritin <30 µg/L with microcytosis) requires bidirectional GI investigation (gastroscopy + colonoscopy), regardless of whether a benign cause of rectal bleeding has been identified. This recommendation is endorsed by the RACGP, GESA, and the British Society of Gastroenterology guidelines adapted for Australian practice.

First-Line Management of Benign Causes (in Primary Care)

When investigation has excluded alarm features and a benign anorectal cause is confirmed:

💊

Paracetamol

Panadol® · Dymadon® · Analgesic

Adult dose 500–1000 mg PO every 4–6 hours (max 4 g/day)

Paediatric dose 15 mg/kg PO every 4–6 hours (max 60 mg/kg/day)

Route / Frequency PO, QID PRN

Duration As needed for anal pain (fissure, thrombosed haemorrhoid)

Renal adjustment eGFR 10–50: max 2 g/day; eGFR <10: max 1 g/day

PBS status ✔ PBS General Benefit

💊

Ferrous Sulfate (Oral Iron Replacement)

Ferro-Gradumet® · Ferro-Liquid® · Iron supplement

Adult dose 325 mg (105 mg elemental iron) PO once daily or on alternate days — alternate-day dosing may improve absorption and tolerability

Paediatric dose 3–6 mg/kg/day elemental iron PO in divided doses

Route / Frequency PO, daily or alternate-day (on empty stomach with vitamin C enhances absorption)

Duration 3–6 months; continue for 3 months after haemoglobin normalisation to replenish stores

Renal adjustment None required

PBS status ✔ PBS General Benefit

💊

Lignocaine 5% Ointment / Hydrocortisone 1% Suppositories

Xylocaine® · Proctosedyl® · Local anaesthetic / anti-inflammatory

Adult dose Lignocaine 5%: apply to perianal area TDS PRN; Hydrocortisone suppositories: 1 suppository BD for up to 7 days

Paediatric dose Not routinely recommended in children <12 years without specialist advice

Route / Frequency Topical / rectal, BD–TDS PRN

Duration Maximum 7 days — prolonged use of topical corticosteroids risks skin atrophy

Renal adjustment None required (minimal systemic absorption)

PBS status ✔ PBS General Benefit (Proctosedyl); ✔ PBS General Benefit (Xylocaine ointment)

Lifestyle and Conservative Measures

Dietary fibre: Increase soluble and insoluble fibre intake to 25–30 g/day — dietary fibre supplements (psyllium husk, e.g., Metamucil®) are PBS-listed for some indications and available OTC
Fluid intake: Adequate hydration (≥1.5–2 L water daily) to soften stool
Toilet habits: Avoid prolonged straining; use a footstool to optimise anorectal angle; respond promptly to the urge to defaecate
Sitz baths: Warm water baths for 10–15 minutes after defaecation can reduce anal sphincter spasm and promote healing in fissures
Weight management: Obesity is an independent risk factor for haemorrhoidal disease and colorectal neoplasia

Referral for Colon Evaluation

Timely referral for colonoscopic evaluation is the cornerstone of managing non-acute LGIB when investigation extends beyond the anorectum or when alarm features are present. The threshold for referral should be low in Australian practice, reflecting the high incidence of colorectal cancer and the proven efficacy of early detection in reducing mortality.

Indications for Colonoscopy Referral

Colonoscopy is the gold standard investigation for evaluating the colonic mucosa. The following indications are based on RACGP, GESA, and Cancer Council Australia guidelines:

🚨

Urgent referral — fast-track (within 2 weeks):

Age ≥50 years with new-onset rectal bleeding
Any age with iron deficiency anaemia and GI symptoms
Unintentional weight loss with rectal bleeding
Palpable rectal or abdominal mass
Change in bowel habit (new constipation, diarrhoea, or looser stools lasting >6 weeks) with bleeding
First-degree relative with CRC diagnosed <60 years + rectal bleeding at any age

⚠️

Semi-urgent referral (within 4–6 weeks):

Age 45–49 years with rectal bleeding (even if likely benign)
Recurrent rectal bleeding (>2 episodes) with no identified anorectal cause
FIT-positive result via NBCSP pathway
Mild iron deficiency (ferritin 15–30 µg/L) without anaemia, in the absence of other alarm features

Age Thresholds and the NBCSP

The Australian National Bowel Cancer Screening Program currently invites Australians for FIT at ages 50, 54, 55, 58, 60, 64, 68, 70, 72, and 74 years (expanding toward biennial screening for all 50–74 year olds). However, in a symptomatic patient with rectal bleeding, the NBCSP age threshold should not delay clinical investigation:

Age ≥50 years with rectal bleeding: Refer for colonoscopy regardless of FIT result — do not wait for a screening FIT to become available
Age 45–49 years with rectal bleeding: Given the rising incidence of early-onset colorectal cancer in Australia, a low threshold for colonoscopy referral is appropriate, particularly with any additional risk factor
Age <45 years, single episode, clear anorectal cause on DRE: May be managed conservatively in primary care with safety-netting; refer if recurrent

Role of FIT in Symptomatic Patients

Faecal immunochemical testing (FIT) quantifies faecal haemoglobin concentration. In the screening (asymptomatic) population, FIT has a sensitivity of approximately 70–75% for colorectal cancer and is the basis of the NBCSP. However, in symptomatic patients:

A negative FIT does not exclude colorectal cancer or significant colonic pathology — sensitivity drops in the symptomatic setting
A positive FIT in a patient with rectal bleeding reinforces the need for colonoscopy but does not add diagnostic value beyond the indication already provided by the bleeding itself
FIT may be most useful in patients with minor, intermittent bleeding where clinical uncertainty exists about whether bleeding is from an anorectal vs. colonic source — a high FIT result (>100 µg Hb/g) supports urgent colonoscopy

Preparing for the Referral

When referring for colonoscopy, the following information should accompany the referral to facilitate triage:

1

Bleeding History

Duration, frequency, character (bright red vs. dark, on surface vs. mixed), volume estimate, relationship to defaecation.

2

Examination Findings

DRE findings (haemorrhoids, fissure, mass, mucus, blood), abdominal examination, vital signs.

3

Investigation Results

FBC (haemoglobin, MCV), ferritin, iron studies, CRP, FIT result if performed.

4

Risk Factors

Family history of CRC (degree of relative, age at diagnosis), personal history of polyps/IBD/CRC, medications (anticoagulants, antiplatelets).

5

Urgency Classification

Specify fast-track (2 weeks) or semi-urgent (4–6 weeks) based on alarm features present.

Alternative and Complementary Investigations

Specialist CT Colonography (Virtual Colonoscopy) MBS Item 57713. An alternative when colonoscopy is incomplete or contraindicated. Requires bowel preparation. Cannot perform biopsies. Sensitivity for polyps ≥10 mm is high (~90%) but drops for smaller lesions. Available at major metropolitan centres.

Specialist Capsule Endoscopy (Small Bowel) MBS Item 11820. Considered when bidirectional endoscopy is negative and ongoing bleeding is suspected from the small bowel. Requires specialist referral. Limited availability in regional and remote Australia.

Specialist CT Angiography / Mesenteric Angiography Reserved for acute or ongoing significant LGIB when endoscopy is non-diagnostic. Requires active bleeding at time of imaging (bleeding rate ≥0.5 mL/min for angiography). Available at tertiary centres.

Available Flexible Sigmoidoscopy MBS Item 32222. Can be performed in the rooms (with or without sedation) and examines the rectum, sigmoid, and descending colon (up to ~60 cm). Useful for initial evaluation of bright red rectal bleeding in younger patients. Does not examine the right colon — colonoscopy preferred if proximal pathology is suspected.

Patient Safety-Netting and Follow-Up

Regardless of the management plan, all patients should receive clear safety-netting advice:

Return promptly if bleeding increases in volume or frequency
Return if dark red or maroon blood develops (suggesting a more proximal source)
Return if new symptoms develop: weight loss, change in bowel habit, abdominal pain, fatigue, dizziness
Follow up within 4–6 weeks to confirm symptom resolution and review investigation results
Patients managed conservatively should have a documented plan for reassessment and a clear timeframe for referral if symptoms persist beyond 4–6 weeks

💡

Australian practice note: Access to colonoscopy varies significantly between metropolitan, regional, and remote areas. Public hospital wait times for non-urgent colonoscopy may exceed 3–6 months in some jurisdictions. Private colonoscopy is generally available within 2–4 weeks. GPs should use local clinical pathways and HealthPathways (where available) to determine the most appropriate referral route. In rural and remote areas, fly-in/fly-out endoscopy services and telehealth may assist with timely access.

Special Populations

👶 Paediatric Patients

Common causes: Anal fissures (most common in infants and young children), allergic proctocolitis (cow's milk protein allergy in infants), juvenile polyps (benign, typically ages 2–8 years), Meckel's diverticulum, IBD (older children and adolescents).

Red flags: Failure to thrive, chronic diarrhoea with blood and mucus, abdominal pain, family history of IBD or polyposis syndromes.

Investigation: FBC, ferritin, faecal calprotectin (MBS Item 66817 — available in Australia, highly sensitive for intestinal inflammation in children). Paediatric gastroenterology referral for colonoscopy if indicated.

Key difference: Colorectal cancer is exceedingly rare in children; investigation is primarily directed toward IBD, polyps, and structural causes.

Ferrous sulfate: 3–6 mg/kg/day elemental iron PO. Available as liquid formulation (Ferro-Liquid®) for young children. ✔ PBS General Benefit

🤰 Pregnancy

Common causes: Haemorrhoids are extremely common in pregnancy (affecting up to 35–40% of pregnant women) due to increased pelvic venous pressure, constipation, and hormonal changes.

Investigation: DRE is safe in pregnancy. Colonoscopy is generally avoided unless strong alarm features are present (discussed case-by-case with gastroenterology and obstetrics). Flexible sigmoidoscopy without sedation may be considered.

Key concern: Iron deficiency is common in pregnancy and must be distinguished from blood loss-related deficiency. Aggressive oral iron replacement is first-line.

Ferrous sulfate 325 mg PO daily/alternate-day: Safe in pregnancy. IV iron (ferric carboxymaltose — Ferinject®) may be required for severe IDA or intolerance to oral iron. ✔ PBS General Benefit (oral); ⚠ PBS Authority Required (IV iron)

👴 Elderly Patients (≥65 years)

Key considerations: Higher prevalence of diverticular disease, angiodysplasia, colorectal cancer, and medication-related bleeding (anticoagulants, antiplatelets). Multiple concurrent causes may coexist.

Comorbidity: Cardiovascular disease may limit tolerability of anaemia — lower threshold for transfusion and iron replacement. Anticoagulation management requires careful balance between thrombotic and bleeding risk.

Colonoscopy: Higher procedural risk in elderly patients (cardiopulmonary complications, sedation risks, bowel preparation adverse effects) but still indicated when alarm features are present. CT colonography may be an acceptable alternative.

Medication review: Assess the necessity of concurrent anticoagulants and antiplatelets. DOACs may require dose adjustment or temporary cessation — discuss with the prescribing specialist. Never discontinue anticoagulation without specialist advice.

🫘 Renal Impairment

Key considerations: Chronic kidney disease (CKD) is associated with increased GI bleeding risk (uraemic platelet dysfunction, anticoagulation for dialysis, angiodysplasia). Iron deficiency is highly prevalent in CKD and may be multifactorial.

Iron replacement: Oral iron absorption is impaired in CKD. IV iron (ferric carboxymaltose or iron polymaltose) is often preferred — PBS Authority Required for IV iron in CKD patients with documented oral intolerance or failure.

Paracetamol: Reduce dose in severe CKD (eGFR <10: max 1 g/day). Avoid NSAIDs entirely.

Bowel preparation: Use polyethylene glycol (PEG)-based preparations (e.g., Movicol®, PrepLYTE®) rather than sodium phosphate-based products, which carry risk of phosphate nephropathy.

🫁 Hepatic Impairment

Key considerations: Portal hypertension can cause colonic portal hypertensive colopathy, which may present with chronic rectal bleeding. Coagulopathy (elevated INR, thrombocytopenia) increases bleeding severity. Known rectal varices should be distinguished from haemorrhoids.

Investigation: Colonoscopy is indicated but requires careful assessment of coagulation status and platelet count. Correct coagulopathy prior to biopsy if safe to do so.

Iron replacement: Oral iron is generally safe. Monitor for worsening of liver function tests in severe hepatic disease. IV iron is preferred when oral iron is not tolerated.

🛡️ Immunocompromised Patients

Key considerations: Patients on immunosuppressants (biologics, corticosteroids, methotrexate, calcineurin inhibitors) or with HIV/AIDS may present with atypical infections (CMV colitis, Kaposi sarcoma) or have reduced inflammatory signs masking serious pathology.

IBD patients: New or changing rectal bleeding in a patient with known IBD may indicate a flare, but must also prompt consideration of superimposed infection (C. difficile) or colorectal neoplasia (increased risk in long-standing colitis).

Investigation threshold: Lower threshold for colonoscopy — atypical presentations are common and delay in diagnosis may be harmful.

Transplant recipients: Post-transplant lymphoproliferative disorder (PTLD) and colorectal cancer risk are increased — maintain high vigilance.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of colorectal cancer compared with non-Indigenous Australians. According to the AIHW, Indigenous Australians are diagnosed with colorectal cancer at a younger age and often present at a later stage, contributing to higher mortality rates. Culturally safe, proactive, and community-embedded approaches are essential to improve outcomes.

Screening participation

NBCSP participation rates among Aboriginal and Torres Strait Islander peoples remain significantly lower than the non-Indigenous population (~30% vs. ~43% nationally). Barriers include lack of awareness, culturally inappropriate health promotion materials, distrust of the healthcare system, and competing health priorities. GP-led discussions about bowel cancer screening during routine consultations can significantly improve uptake.

Remote and rural access

Many Aboriginal and Torres Strait Islander Australians live in remote and very remote areas where access to colonoscopy, specialist gastroenterology services, and pathology is severely limited. Fly-in/fly-out endoscopy services exist but have limited capacity. Ring-fenced colonoscopy access for Indigenous patients with alarm features is recommended to reduce wait times and improve equity.

Health literacy and communication

Health literacy levels vary widely. Discussions about rectal bleeding, colonoscopy bowel preparation, and cancer risk should use plain, non-judgemental language with cultural sensitivity. Aboriginal Health Workers and Aboriginal Liaison Officers are invaluable in facilitating communication and trust. Ensure patient consent processes are culturally appropriate and, where needed, conducted with interpreter support for speakers of Aboriginal and Torres Strait Islander languages.

Comorbidities and competing risks

High rates of chronic disease (cardiovascular disease, diabetes, chronic kidney disease, rheumatic heart disease) may overshadow the investigation of rectal bleeding. Iron deficiency is prevalent due to poor nutrition, chronic disease, and parasitic infections (in some communities). GPs should integrate bowel health assessment into chronic disease management plans (MBS Item 721 / 723).

Stigma and normalisation

Rectal bleeding may be normalised or considered embarrassing, leading to delayed presentation. Community education campaigns should normalise conversations about bowel health and destigmatise symptoms. Use of Aboriginal community-controlled health organisations (ACCHOs) as trusted settings for health promotion is strongly encouraged.

Follow-up and safety-netting

Patients in remote communities may face significant logistical barriers to attending follow-up appointments or specialist referrals. Proactive follow-up through ACCHOs, use of My Health Record for care coordination, and telehealth consultations (MBS Items 91790, 91800, 91801 for telehealth) can help bridge these gaps. Ensure referrals are accompanied by clear communication to the receiving service about cultural considerations and logistical support needs.

✅

Practical recommendations: Initiate bowel health discussions as part of routine Aboriginal and Torres Strait Islander health assessments (MBS Item 715). Ensure that investigations and referrals are actioned — not just recommended — with active follow-up by the practice team. Partner with local Aboriginal Health Workers to deliver culturally appropriate bowel cancer screening promotion. Document advance care planning conversations where relevant, particularly for elderly patients with complex comorbidities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Cancer data in Australia. Cat. no. CAN 122. Canberra: AIHW; 2023.
2. Cancer Council Australia Colorectal Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia; 2017. Available at: wiki.cancer.org.au/australiawiki/index.php?oldid=181103.
3. National Health and Medical Research Council (NHMRC). National bowel cancer screening program: modelling of the transition to biennial screening. Canberra: NHMRC; 2022.
4. Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol. 2016;111(5):712–721.
5. Oakland K, Chadwick G, East JE, et al. Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology. Gut. 2019;68(5):776–789.
6. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 9th edn. Melbourne: RACGP; 2018.
7. Gastroenterological Society of Australia (GESA). Colonoscopy clinical care standards. Melbourne: GESA; 2020.
8. Young GP, Symonds EL, Allison JE, et al. Advances in colorectal cancer screening and diagnosis: the role of fecal immunochemical tests. Clin Gastroenterol Hepatol. 2022;20(3):479–489.
9. Australian Institute of Health and Welfare (AIHW). The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. Cat. no. IHW 230. Canberra: AIHW; 2023.
10. Con D, De Cruz P. Endoscopic evaluation and management of lower gastrointestinal bleeding. Aust Fam Physician. 2018;47(10):694–698.
11. Sengupta N, Tapper EB. Lower gastrointestinal bleeding: epidemiology and outcomes. Gastroenterol Clin North Am. 2022;51(1):1–13.
12. National Bowel Cancer Screening Program (NBCSP). Program overview and participation data. Australian Government Department of Health and Aged Care; 2024. Available at: www.health.gov.au/our-work/national-bowel-cancer-screening-program.
13. Goddard AF, James MW, McIntyre AS, Scott BB; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309–1316.